HAIFA, Israel — August 27, 2025 — Leads & Copy — Minovia Therapeutics Ltd., a clinical-stage biotechnology company focused on therapies for mitochondrial diseases and age-related decline, will receive a $350,000 grant from Countdown for a Cure for research into novel mitochondrial blood-based biomarkers.
Dr. Noa Sher, Minovia’s CSO, said the funds will help advance the development of blood-based functional mitochondrial biomarkers. These biomarkers are expected to help identify patients who could benefit from Minovia’s mitochondrial augmentation technology (MAT) and assist in patient follow-up after MAT treatment. Minovia also aims to develop biomarkers to quantify mitochondrial content, quality, and function, determining mitochondrial scores for healthy individuals versus those with mitochondrial diseases. A clinical trial at Sheba Medical Center is collecting blood samples from healthy volunteers and mitochondrial disease patients, with the grant funding clinical operations for blood sample collection from about 30 patients with primary mitochondrial diseases and 140 healthy controls. The samples will undergo analysis in Minovia’s labs utilizing newly developed biomarkers, and a MitoScore will be determined for each sample. The funding will also support the development of new biomarkers using novel research tools.
Minovia recently announced a business combination agreement with Launch One Acquisition Corp. (Nasdaq: LPAA), with the combined company expected to operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol after the transaction closes, projected for late 2025.
Mitochondrial dysfunction occurs in rare genetic mitochondrial diseases, as well as in chronic and age-related diseases. There is a need for treatment of these diseases, as there are currently no approved therapies for mitochondrial dysfunction and no functional tests to diagnose and quantify mitochondrial dysfunction in individuals of all ages.
Contact:
Natalie Yivgi Ohana, Co-Founder and CEO
+972-74-7039954
info@minoviatx.com
Source: Minovia Therapeutics Ltd.
